Impact of Saccharomyces boulardii on jaundice in premature infants undergoing phototherapy

Hu, Di; Wang, Ying; Yang, Suyan; Zhang, Huijuan

doi:10.1016/j.jped.2022.10.010

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In numerous studies, the findings showed that the addition of oral probiotics/prebiotics/synbiotics to phototherapy is associated with a higher bilirubin reduction rate, reduced phototherapy duration, and shorter hospitalization (31)(32)(33)(34)(35). In addition, S. boulardii, in combination with phototherapy, was effective and safe in reducing bilirubin levels and duration of phototherapy in icteric premature infants in Hu et al's study (36). On the other hand, a meta-analysis by Chen et al showed that probiotics supplementation is an effective and safe adjunctive treatment for pathological neonatal IHB (37).…”

Section: Probiotics Prebiotics and Synbioticsmentioning

confidence: 96%

Recent Advances in Adjuvant Pharmacotherapy for Neonatal Indirect Hyperbilirubinemia: A Narrative Review

Nouri

Zarkesh

2023

J Compr Ped

View full text Add to dashboard Cite

Context: Hyperbilirubinemia is a common cause for diagnostic work-up and therapeutic intervention in neonates and needs a convenient, quick, and safe treatment modality. Phototherapy is the most common treatment for neonatal jaundice; however, complementary treatment is still needed. Despite the identification of the enzymatic pathways of bilirubin catabolism, few pharmacological interventions have been found to be effective in reducing bilirubin, along with traditional phototherapy. This review was conducted to evaluate recent pharmacotherapies as adjuvants to phototherapy for the treatment of neonatal indirect hyperbilirubinemia (IHB). Evidence Acquisition: This study was carried out through a literature search with the keywords of Infant, Newborn, and Indirect Hyperbilirubinemia, combined with Drug Therapy, in PubMed, Scopus, International Statistical Institute, Web of Science, Cochrane, and Embase databases. This study included relevant articles (i.e., randomized controlled trials, observational studies, guidelines, and reviews) written in English and published between 2012 - 2022. Results: This narrative review first assessed the relevant articles to define IHB and its etiology. Then, the efficacy and side effects of recent pharmacologic agents as adjuvants to phototherapy were discussed. Additionally, this study reviewed the efficacy and safety of drugs prescribed to neonates to prevent jaundice. Conclusions: The best drug for adjuvant pharmacotherapy, in addition to phototherapy, for neonatal jaundice has not still been identified. The use of probiotics, prebiotics, synbiotics, and ursodeoxycholic acid (UDCA) in adjuvant to phototherapy has been recently increasing, and beneficial results were observed in most studies. The use of agar, charcoal, fibrate, and phenobarbital had a minor therapeutic role in recent years. There were conflicting results about the efficacy of herbal agents in neonatal jaundice. The use of intravenous immunoglobulin (IVIG), metalloporphyrin, and albumin is also limited to severe or immune-related IHB cases. The prescription of the aforementioned drugs sometimes had different results. Therefore, further research in this regard is necessary.

show abstract

Section: Probiotics Prebiotics and Synbioticsmentioning

confidence: 96%

Recent Advances in Adjuvant Pharmacotherapy for Neonatal Indirect Hyperbilirubinemia: A Narrative Review

Nouri

Zarkesh

2023

J Compr Ped

View full text Add to dashboard Cite

show abstract

“…A meta-analysis that included data from 13 articles based on 1067 newborns provided evidence that combined routine therapy with supplemental probiotic therapy, consisting of Bifidobacterium, S. boulardii, C. butyricum, probiotic oligosaccharides, and B. subtilis, was clearly effective in treating neonatal jaundice. The supplemental probiotics not only improved the treatment outcomes by significantly reducing the total bilirubin and jaundice resolution time, but it also reduced the duration of phototherapy and length of hospitalization, without serious adverse reactions [88,89]. Another study evaluated the effects of probiotic supplementation on neonates with indirect jaundice induced by isoimmunization alone, and showed no differences in the rate of bilirubin reduction in the first 24 h of life.…”

Section: Probioticsmentioning

confidence: 99%

“Light” on Phototherapy—Complications and Strategies for Shortening Its Duration, A Review of the Literature

Shoris,

Gover,

Toropine

et al. 2023

Children

View full text Add to dashboard Cite

Neonatal hyperbilirubinemia is an extremely common metabolic complication of the neonatal period which may be associated with bilirubin encephalopathy and even death. Adverse neurological consequences are preventable if a timely diagnosis and treatment are provided. Phototherapy is usually the preferred option to decrease hyperbilirubinemia. Although considered to be safe, evidence in recent years has shown that this treatment may not be free of side effects and short- and long-term unfavorable outcomes. These are usually mild or rare, but should be decreased or avoided if possible. Many useful complementary measures and treatments have been described that could shorten the duration of exposure to phototherapy. However, there is no current unequivocal recommendation to use any of the methods presented in this review. Our review aims to depict the wide range of possible complementary treatments to phototherapy, and to provide the scientific and clinical evidence available regarding their usefulness. It is essential that, while utilizing the full potential of phototherapy to treat hyperbilirubinemia, caregivers are aware of its side effects and possible inherent dangers, and seek ways to minimize the exposure to phototherapy to what is really needed for the newborn. Further studies are needed to clarify the preferred complementary treatments that could reduce the duration of exposure to phototherapy without impairing its effectiveness.

show abstract

Effect of Saccharomyces boulardii on Liver Diseases: A Systematic Review

Maslennikov,

Benuni,

Levshina

et al. 2024

Microorganisms

View full text Add to dashboard Cite

We aimed to systematize the results of published studies on the use of Saccharomyces boulardii (SB) for the treatment of various liver disorders (CRD42022378050). Searches were conducted using PubMed and Scopus on 1 August 2022. The PubMed search was updated on 15 June 2024. The review included sixteen studies: ten experimental animal studies (EASs) and six randomized controlled trials (RCTs). The CNCM I-745 strain was used in 68.8% of the included studies. SB reduced the severity of many manifestations of cirrhosis, and lowered the Child–Pugh scores in RCT. SB reduced the serum concentrations of TNF-α, IL-1β, IL-6, and IL-4 in animals with metabolic dysfunction-associated steatotic liver disease (MASLD); lowered the serum TNF-α and IL-6 levels in experimental cirrhosis in rats; and reduced the CRP levels in decompensated cirrhosis. The EAS of MASLD revealed that SB reduced liver steatosis and inflammation and lowered the liver expression of genes of TNF-α, IL-1β, interferon-γ, and IL-10. In studies on experimental cirrhosis and MASLD, SB reduced the liver expression of genes of TGF-β, α-SMA, and collagen as well as liver fibrosis. SB reduced the abundance of Escherichia (Proteobacteria), increased the abundance of Bacteroidetes in the gut microbiota, prevented an increase in intestinal barrier permeability, and reduced bacterial translocation and endotoxemia.

show abstract

Impact of Saccharomyces boulardii on jaundice in premature infants undergoing phototherapy

Cited by 3 publications

References 30 publications

Recent Advances in Adjuvant Pharmacotherapy for Neonatal Indirect Hyperbilirubinemia: A Narrative Review

Recent Advances in Adjuvant Pharmacotherapy for Neonatal Indirect Hyperbilirubinemia: A Narrative Review

“Light” on Phototherapy—Complications and Strategies for Shortening Its Duration, A Review of the Literature

Effect of Saccharomyces boulardii on Liver Diseases: A Systematic Review

Contact Info

Product

Resources

About